Sep 18, 2018
Vifor Pharma Group increases equity stake in ChemoCentryx from 6.6% to 21.2%. Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (NASDAQ: CCXI) from...
Aug 28, 2018
Vifor Pharma today announced the launch of an inaugural Swiss Franc straight bond in the amount of CHF 465 million in the Swiss domestic market. The bond carries a 0.75% fixed coupon with a tenor...
Aug 8, 2018
Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track #Strategic in-licensing deal concluded with Cara Therapeutics Inc Net sales and EBITDA guidance...
May 23, 2018VFMCRP and CARA Therapeutics to develop and commercialise CR845 injection for Chronic kidney disease-associated pruritu
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...
May 15, 2018
All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...